Q&A: Phase 1b trial will assess oral-administered vascular adhesion protein-1 inhibitor for NASH

Q&A: Phase 1b trial will assess oral-administered vascular adhesion protein-1 inhibitor for NASH

Terns Pharmaceuticals Inc. announced initiation of a phase 1b clinical trial assessing TERN-201 for the treatment of patients with nonalcoholic steatohepatitis.According to a press release, TERN-201 is an orally administered inhibitor of vascular adhesion protein-1 (VAP-1). The AVIATION trial is a multi-center, randomized, double-blind, dose-ranging, placebo-controlled, phase 1b clinical study of the safety, pharmacokinetics, pharmacodynamics and efficacy of TERN-201 in patients with presumed non-cirrhotic NASH and a cT1 value of greater than 800ms. Researchers will compare the safety andRead More

Share on facebook
Share on twitter
Share on linkedin